HC Wainwright Issues Optimistic Estimate for TARA Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – HC Wainwright increased their FY2026 earnings per share estimates for Protara Therapeutics in a research report issued on Monday, November 9th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of ($1.35) for the year, up from their prior estimate of ($1.38). The consensus estimate for Protara Therapeutics’ current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q4 2026 earnings at ($0.34) EPS, Q1 2027 earnings at ($0.34) EPS, Q2 2027 earnings at ($0.34) EPS, Q3 2027 earnings at ($0.34) EPS, Q4 2027 earnings at ($0.34) EPS, FY2027 earnings at ($1.37) EPS and FY2028 earnings at ($0.41) EPS.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings results on Friday, November 6th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.02.

TARA has been the topic of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Wall Street Zen raised Protara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Protara Therapeutics in a research report on Thursday, October 15th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $26.25.

Protara Therapeutics Trading Down 3.2%

Shares of NASDAQ:TARA opened at $2.43 on Wednesday. The company’s 50-day moving average price is $2.97 and its 200 day moving average price is $4.46. Protara Therapeutics has a fifty-two week low of $2.09 and a fifty-two week high of $7.82.

Institutional Trading of Protara Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its holdings in shares of Protara Therapeutics by 133.9% in the first quarter. Dimensional Fund Advisors LP now owns 531,267 shares of the company’s stock valued at $2,767,000 after acquiring an additional 304,110 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Protara Therapeutics during the second quarter worth approximately $526,000. Bank of America Corp DE boosted its stake in Protara Therapeutics by 86.7% during the 1st quarter. Bank of America Corp DE now owns 925,918 shares of the company’s stock valued at $4,824,000 after purchasing an additional 430,014 shares in the last quarter. Walleye Capital LLC boosted its position in shares of Protara Therapeutics by 204.0% during the 1st quarter. Walleye Capital LLC now owns 443,401 shares of the company’s stock valued at $2,310,000 after purchasing an additional 297,525 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Protara Therapeutics by 22.2% in the 1st quarter. The Manufacturers Life Insurance Company now owns 13,548 shares of the company’s stock worth $71,000 after acquiring an additional 2,464 shares during the last quarter. 38.13% of the stock is currently owned by institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company’s lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer. Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications.